



State Chest Conference

YaleCME
CONTINUING MEDICAL EDUCATION

Presented by

Yale School of Medicine's Department of Internal Medicine - Section of Pulmonary, Critical Care & Sleep Medicine

Diagnosing and Treating Fibrotic Lung Disease



Toby Maher, MD, PhD

British Lung Foundation Chair in Respiratory Research and National Institute for Health Research Clinician Scientist

Professor of Interstitial Lung Disease, Imperial College, London

Director of Respiratory Research and Consultant Respiratory Physician, Royal Brompton Hospital

Wednesday, November 14, 2018, 3-4 pm

Fitkin Amphitheatre

Moderator: Erica Herzog, MD, PhD

There is no corporate support for this activity

This course will fulfill the licensure requirement set forth by the State of Connecticut

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

NEEDS ASSESSMENT

Fibrotic lung disease results in high levels of morbidity and mortality. Diagnosis is often considered challenging and, despite international guidelines, misdiagnosis is frequent. Importantly, the advent of effective anti-fibrotic therapies, combined with the development of disease modifying treatments for conditions characterised by pulmonary fibrosis including connective tissue disease has made the need for accurate diagnosis of vital importance. This talk will address understanding of how to diagnose and classify fibrotic lung disease and will explore the currently available treatment options for IPF, chronic hypersensitivity pneumonitis and connective tissue disease associated interstitial lung disease.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will learn to:

1. Explore diagnosis and classification of fibrotic lung disease
2. Describe currently available therapies and drugs in development for fibrotic lung disease
3. Discuss an algorithm for selecting therapy for individuals with lung fibrosis

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*[™]. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Richard Matthay, MD, Course Director – No conflicts of interest
Toby Maher, MD, PhD – Roche/Genentech, Boehringer Ingelheim, Galapagos

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.